Patent application number | Description | Published |
20100260367 | HEARING INSTRUMENT AND INPUT METHOD FOR A HEARING INSTRUMENT - A hearing instrument comprises an openable cover lid, the cover lid comprising at least one electrical input element and at least one lid contact terminal arranged to physically and electrically contact at least one corresponding device contact terminal when the lid is in a closed position. The cover lid further comprises at least two electrical input, each of the at least two input elements being functionally associated with the impedance between the lid contact terminal and a further terminal, and the hearing instrument comprises means to infer the state of the input elements from said impedance. In a preferred embodiment, the number of input elements is equal to or larger than the number of lid contact terminals. In a further embodiment, the lid is the lid of a battery compartment of the hearing instrument, and in a closed position of the lid at least one of the input elements is in electrical contact with one of the terminals of a battery lying in the battery compartment. | 10-14-2010 |
20110091060 | HEARING INSTRUMENT - A hearing instrument includes a behind-the-ear component and an external component for being placed in the user's ear canal or in the user's ear and a connection link between the behind-the-ear component and the external component. The connection link is reversibly pluggable to the behind-the-ear component and/or the in-the-ear-canal component and has a length that is reversibly adjustable. Fixation means is provided for reversibly fixing the adjusted length of the connection link. The in-the-ear-canal component may be connected to the fixation means and detached therefrom when the same is in the ear canal. An in-the-ear-canal component to be placed in a user's ear canal can have fixation means for fixing it in the ear canal. The fixation means includes an outer shell shaped to fit in the user's ear canal and a mounting structure for holding the in-the-ear-canal component. The outer shell is preferably resilient, with an elasticity allowing temporal deformation. | 04-21-2011 |
20110091061 | HEARING INSTRUMENT - A hearing instrument with at least one microphone and signal processing includes at least two receivers having a different frequency response. At least a first one of the receivers can be placed outside the ear canal, for example in a behind-the-ear component. A behind-the-ear component and an external component can be provided for being placed in the user's ear canal or in the user's ear with a connection link between the behind-the-ear component and the external component. The sound processing means can feed the first receiver with a first signal of a first central frequency and the second receiver with a second signal of a second central frequency. The signal processing means can be one or two signal processing units. A frequency separating filter can have an input operatively connected to an output of the signal processing unit. | 04-21-2011 |
Patent application number | Description | Published |
20130183368 | P97-ANTIBODY CONJUGATES AND METHODS OF USE - The present invention provides p97-antibody conjugates and related compositions and methods, which may be used in any of a variety of therapeutic methods, including methods for the treatment of cancers such as Her2/neu-expressing and Her1/EGFR-expressing cancers. | 07-18-2013 |
20140178350 | DEPHOSPHORYLATED LYSOSOMAL STORAGE DISEASE PROTEINS AND METHODS OF USE THEREOF - Provided are substantially dephosphorylated forms of lysosomal storage disease (LSD) proteins, including dephosphorylated forms of iduronate-2-sulfatase (IDS, or I2D) and iduronidase (IDU), having increased ability to traverse or penetrate the blood brain barrier (BBB) relative to phosphorylated forms of the protein, and p97 conjugates thereof. Also provided are compositions comprising such dephosphorylated LSD proteins and p97 conjugates, and methods of use thereof, for instance, to treat any one or more lysosomal storage diseases, such as Hunter Syndrome (or MPS Type II). | 06-26-2014 |
20140322132 | FRAGMENTS OF P97 AND USES THEREOF - Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising said p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB. | 10-30-2014 |
20150147314 | CURCUPHENOL COMPOUNDS FOR INCREASING MHC-I EXPRESSION - Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies. | 05-28-2015 |
Patent application number | Description | Published |
20110112036 | PHARMACEUTICAL COMPOSITIONS OF PACLITAXEL, PACLITAXEL ANALOGS OR PACLITAXEL CONJUGATES AND RELATED METHODS OF PREPARATION AND USE - Pharmaceutical compositions useful for hydrophobic agents paclitaxel, paclitaxel analogs and conjugates thereof (e g ANG1005) which do not contain Cremophor™ The compositions further comprise an optional tonicity agent, a buffering agent a bulking agent and a solubilizmg agent which is not Cremophor™ Methods of preparing said compositions and of said compositions in the treatment of cancer are also included. | 05-12-2011 |
20120135914 | ETOPOSIDE AND DOXORUBICIN CONJUGATES FOR DRUG DELIVERY - The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides having a hydrolyzable covalent bond to a therapeutic agent that includes, etoposide, etoposide 4′-dimethylglycine or doxorubicin. These polypeptide conjugates can be used as vectors to transport the podophyllotoxin derivative across the blood brain barrier (BBB) or into particular cell types such as ovary, liver, lung, or kidney. The invention also relates to pharmaceutical compositions that include the compounds of the invention and to uses thereof in methods of treatment. | 05-31-2012 |
20150038429 | ETOPOSIDE AND DOXORUBICIN CONJUGATES FOR DRUG DELIVERY - The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides having a hydrolyzable covalent bond to a therapeutic agent that includes, etoposide, etoposide 4′-dimethylglycine or doxorubicin. These polypeptide conjugates can be used as vectors to transport the podophyllotoxin derivative across the blood brain barrier (BBB) or into particular cell types such as ovary, liver, lung, or kidney. The invention also relates to pharmaceutical compositions that include the compounds of the invention and to uses thereof in methods of treatment. | 02-05-2015 |